Gene therapy injection aims to halt blinding eye disease

NCT ID NCT07602127

Not yet recruiting Disease control Sponsor: Zhongmou Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a gene therapy called AGX-08 for geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. The study will involve 24 people aged 50 and older, each receiving a single injection into one eye. The main goal is to check safety, but researchers will also measure changes in vision and retinal health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AGX-08 (gene therapy injection into the eye)
What this could lead to: If it works, this could point toward a treatment that slows or stops vision loss from geographic atrophy.
What could go wrong: This is a very early, first-in-human trial with only 24 people. It primarily checks safety, not effectiveness, and may fail or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GEOGRAPHIC ATROPHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.